The US Food and Drug Administration granted its first approval to an immunotherapy regimen for breast cancer, the agency announced Friday. The drug, Genentech's Tecentriq, was approved for use in combination with Abraxane chemotherapy for patients who have a type of advanced triple negative breast cancer.
from CNN.com - RSS Channel https://ift.tt/2VLnxWE
via
No comments:
Post a Comment